BRPI0600194A - composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas - Google Patents

composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas

Info

Publication number
BRPI0600194A
BRPI0600194A BRPI0600194-7A BRPI0600194A BRPI0600194A BR PI0600194 A BRPI0600194 A BR PI0600194A BR PI0600194 A BRPI0600194 A BR PI0600194A BR PI0600194 A BRPI0600194 A BR PI0600194A
Authority
BR
Brazil
Prior art keywords
docetaxel
degradation inhibitor
pharmaceutical compositions
containing pharmaceutical
obtaining same
Prior art date
Application number
BRPI0600194-7A
Other languages
English (en)
Inventor
Eneida Guimaraes
Livia Sampaio Machado
Marcio Ronaldo Junior Santiago
Maria Mirtes Da Silva
Richard Michel Grazul
Antenio Salustiano Machado
Original Assignee
Quiral Quimica Do Brasil S A
Biorganica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quiral Quimica Do Brasil S A, Biorganica Ltda filed Critical Quiral Quimica Do Brasil S A
Priority to BRPI0600194-7A priority Critical patent/BRPI0600194A/pt
Priority to JP2008554552A priority patent/JP2009524700A/ja
Priority to EP06721578A priority patent/EP1978953A1/en
Priority to PCT/BR2006/000016 priority patent/WO2007085067A1/en
Priority to MX2008009705A priority patent/MX2008009705A/es
Priority to CA002640950A priority patent/CA2640950A1/en
Priority to CNA2006800540696A priority patent/CN101415416A/zh
Priority to US12/162,772 priority patent/US20090221688A1/en
Priority to RU2008131308/15A priority patent/RU2408362C2/ru
Publication of BRPI0600194A publication Critical patent/BRPI0600194A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS CONTENDO DOCETAXEL E UM INIBIDOR DE DEGRADAçãO E PROCESSO DE OBTENçãO DAS MESMAS Composição Farmacêutica contendo um ácido orgânico com pKa entre 2,5-4,5 utilizado como inibidor de degradação, polissorbato 80 e docetaxel anidro (I) ou o seu triidrato. As composições obtidas são estéreis e estáveis até 30 meses quando armazenadas a temperatura ambiente, Correspondente à faixa de 15 a 30<198>C, ± 1<198>C, e apresentam baixos teores de 7-epi--docetaxel (II).
BRPI0600194-7A 2006-01-30 2006-01-30 composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas BRPI0600194A (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0600194-7A BRPI0600194A (pt) 2006-01-30 2006-01-30 composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
JP2008554552A JP2009524700A (ja) 2006-01-30 2006-02-09 ドセタキセルと分解阻害剤を含む医薬組成物およびその医薬組成物の製造方法
EP06721578A EP1978953A1 (en) 2006-01-30 2006-02-09 Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same.
PCT/BR2006/000016 WO2007085067A1 (en) 2006-01-30 2006-02-09 Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same.
MX2008009705A MX2008009705A (es) 2006-01-30 2006-02-09 Composiciones farmaceuticas que contienen docetaxel, un inhibidor de degradacion y un proceso para obtener el mismo.
CA002640950A CA2640950A1 (en) 2006-01-30 2006-02-09 Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same
CNA2006800540696A CN101415416A (zh) 2006-01-30 2006-02-09 含多西他赛和降解抑制剂的药物组合物及其制备方法
US12/162,772 US20090221688A1 (en) 2006-01-30 2006-02-09 Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same
RU2008131308/15A RU2408362C2 (ru) 2006-01-30 2006-02-09 Фармацевтическая композиция, содержащая доцетаксель и ингибитор деградации, и способ ее получения

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0600194-7A BRPI0600194A (pt) 2006-01-30 2006-01-30 composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas

Publications (1)

Publication Number Publication Date
BRPI0600194A true BRPI0600194A (pt) 2007-10-23

Family

ID=38603030

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0600194-7A BRPI0600194A (pt) 2006-01-30 2006-01-30 composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas

Country Status (9)

Country Link
US (1) US20090221688A1 (pt)
EP (1) EP1978953A1 (pt)
JP (1) JP2009524700A (pt)
CN (1) CN101415416A (pt)
BR (1) BRPI0600194A (pt)
CA (1) CA2640950A1 (pt)
MX (1) MX2008009705A (pt)
RU (1) RU2408362C2 (pt)
WO (1) WO2007085067A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
KR100878455B1 (ko) * 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
US8686165B2 (en) * 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
CN101708177B (zh) * 2009-11-23 2012-09-05 浙江万马药业有限公司 一种含多西他赛的药物组合物及其制备方法
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
CN103906747A (zh) * 2011-10-31 2014-07-02 台湾神隆股份有限公司 卡巴他赛及其中间体的制备方法
CN103159705B (zh) * 2011-12-12 2015-05-27 福建南方制药股份有限公司 卡巴他赛中间体的制备方法
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
JP5847942B2 (ja) * 2012-07-19 2016-01-27 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EA024176B1 (ru) * 2014-03-05 2016-08-31 Республиканское Унитарное Производственное Предприятие "Белмедпрепараты" (Руп "Белмедпрепараты") Способ получения противоопухолевого препарата на основе доцетаксела
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
CN111557934A (zh) * 2020-06-10 2020-08-21 四川汇宇制药股份有限公司 一种含多西他赛的药物组合物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
CA2404370A1 (en) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
CN1241561C (zh) * 2002-12-16 2006-02-15 天津大学 紫杉烷类的注射药制剂
US20040171560A1 (en) * 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
EP1694660B1 (en) * 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
CN101151349B (zh) 2005-03-31 2011-04-13 三菱化学株式会社 防恶化剂
EP2138164A1 (en) * 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
CN100408032C (zh) 2006-01-18 2008-08-06 深圳万乐药业有限公司 一种稳定的多西他赛注射剂
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas

Also Published As

Publication number Publication date
JP2009524700A (ja) 2009-07-02
CA2640950A1 (en) 2007-08-02
MX2008009705A (es) 2008-10-08
WO2007085067A1 (en) 2007-08-02
RU2008131308A (ru) 2010-03-10
RU2408362C2 (ru) 2011-01-10
CN101415416A (zh) 2009-04-22
EP1978953A1 (en) 2008-10-15
US20090221688A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
MX2008009705A (es) Composiciones farmaceuticas que contienen docetaxel, un inhibidor de degradacion y un proceso para obtener el mismo.
UY30759A1 (es) Compuestos quimicos
MX353841B (es) Composiciones antimicrobianas y metodos de uso.
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
BR112012014721A2 (pt) composição de hormônio do crescimento
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
DE60310564D1 (de) Injizierbare depotformulierung enthaltend iloperidonkrystalle
GT200600246A (es) Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
BR0116369A (pt) Composto, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, uso de um composto, e, processo para preparar composto
AR035039A1 (es) COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
BRPI0516725A (pt) composições de encapsulação de alta resistência à tração, termicamente estável, para ativos
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BRPI0513701A (pt) composição de inseticidas à base de neonicotinóides e protetores, uso e processo para combater artrópodes e uso e processo para proteger a semente
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
AR061165A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
BRPI0416674A (pt) tiazolidinona amidas, amidas de ácido tiazolidino carboxìlico, processos de fabricação, e uso das mesmas

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: ARQUIVAMENTO DEFINITIVO

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2271 DE 15/07/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A, 10A, 11A, 12A, 13A E 14A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.